Search | Clinical Trials Finder

Conditions: Type 2 Diabetes Mellitus, Hypercholesterolemia, Pre-diabetes
Interventions: Metformin HCl and Colesevelam Placebo, Metformin HCl tablets and Colesevelam tablets, Colesevelam placebo, Colesevelam; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 502 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 17
States / cities: Birmingham, Alabama • Los Gatos, California • Tarzana, California + 14 more

Conditions: Lung Cancer - Non Small Cell Squamous
Interventions: Ipilimumab, Placebo, Paclitaxel, Carboplatin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 33
States / cities: San Diego, California • West Haven, Connecticut • Boca Raton, Florida + 29 more

Conditions: Prediabetic State
Interventions: GlucoSupreme™ Herbal, Placebo; Dietary Supplement · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 4
States / cities: Baltimore, Maryland • Cincinnati, Ohio

Conditions: Hypoglycemia
Interventions: Glucagon-only bionic pancreas - glucagon, Glucagon-only bionic pancreas - placebo; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 21 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity, Overweight
Interventions: Ribupatide, Placebo; Drug
Lead sponsor: Kailera; Industry
Eligibility: 18 Years and older
Enrollment: 2,340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 24
States / cities: Anniston, Alabama • Birmingham, Alabama • Cullman, Alabama + 21 more

Conditions: Type 2 Diabetes
Interventions: chromium picolinate 1000 mcg daily vs placebo, Placebo; Dietary Supplement · Other
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 25 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Urinary Urge Incontinence
Interventions: Oxybutynin extended release, Posterior Tibial Nerve Stimulation, Placebo; Drug · Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Durham, North Carolina • Raleigh, North Carolina

Conditions: Cardiovascular Disease, Diabetes Mellitus Type 2
Interventions: Placebo, aleglitazar; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 40 Years and older
Enrollment: 1,999 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 143
States / cities: Muscle Shoals, Alabama • Gilbert, Arizona • Phoenix, Arizona + 126 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Pramlintide acetate, Placebo, Lispro insulin U-100, Regular insulin U-100; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Chula Vista, California • Portland, Oregon • Chattanooga, Tennessee

Conditions: Sarcopenia
Interventions: bimagrumab, placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 70 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 17
States / cities: Little Rock, Arkansas • Cypress, California • La Jolla, California + 14 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin icodec, Placebo (insulin 287), Metformin, Dipeptidyl peptidase-4 inhibitors, Insulin glargine, Placebo (insulin glargine); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 14
States / cities: Lancaster, California • Ventura, California • Walnut Creek, California + 9 more

Conditions: Metabolic Syndrome
Interventions: Melatonin, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 30 Years to 79 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Polycystic Ovary Syndrome
Interventions: Metformin, Oral Contraceptive Pill, Lifestyle Management Program, Quality of Life Questionnaire, Oral Glucose Tolerance Test, Blood work, Abdominal Ultra Sound, Dual-energy x-ray absorptiometry (DEXA scan), placebo; Drug · Behavioral · Procedure
Lead sponsor: University of Rochester; Other
Eligibility: 12 Years to 18 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Diabetes Mellitus, Type 1
Interventions: Parenteral Insulin, Close Observation, Oral Insulin, Placebo; Drug · Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 3 Years to 45 Years
Enrollment: 711 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1994 – 2003
U.S. locations: 14
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 10 more

Conditions: Insulin Resistance, Hyperinsulinemia, Dyslipidemias
Interventions: Alpelisib 150 mg [Piqray], 2 overencapsulated tablets (total: 300 mg), Placebo (microcrystalline cellulose), 2 capsules, FreeStyle Libre Pro, Oral glucose tolerance test (OGTT) with Trutol glucose beverage, BOOST Plus nutritional beverage; Drug · Device · Diagnostic Test + 1 more
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Carcinoma, Non Small Cell Lung
Interventions: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Placebo, Docetaxel (Taxotere®), Dexamethasone (pre- and post-medication for docetaxel); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 913 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Diabetes Mellitus
Interventions: TAK-379, Pioglitazone, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 8
States / cities: Artesia, California • Norwalk, California • Santa Ana, California + 5 more

Conditions: Prediabetes
Interventions: Blood Sugar Take Care, Placebo; Dietary Supplement
Lead sponsor: NewChapter, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Diet Modification
Interventions: Low fiber, Placebo, High fiber; Dietary Supplement
Lead sponsor: University of Minnesota; Other
Eligibility: 20 Years to 49 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Healthy
Interventions: Oritavancin, Dextrose; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Salt; Excess, Hypertension, Aging, Inflammation, Blood Pressure
Interventions: No Salt, No β-OHB, High Salt, No β-OHB, High Salt, High β-OHB; Dietary Supplement
Lead sponsor: Indiana University; Other
Eligibility: 50 Years to 85 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Bloomington, Indiana

Conditions: Diabetes Mellitus, Type 2
Interventions: CS-917, metformin hydrochloride, pioglitazone; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 66
States / cities: Birmingham, Alabama • Northport, Alabama • Mesa, Arizona + 62 more

Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Retinopathy of Prematurity, Bronchopulmonary Dysplasia (BPD)
Interventions: Inositol lower volume, Inositol higher volume, Placebo lower volume, Placebo higher volume; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 3 Days to 6 Days
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 11
States / cities: New Haven, Connecticut • Indianapolis, Indiana • Detroit, Michigan + 7 more

Conditions: Portal Hypertension, Liver Cirrhosis
Interventions: Ifetroban, Placebo; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 6
States / cities: Tampa, Florida • Indianapolis, Indiana • Columbus, Ohio + 3 more

Search by objective public record fields.

Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.

Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin

RCT of a Polyherbal Dietary Supplement for Prediabetes

Post Bariatric Closed Loop Glucagon Trial

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

Effect of Chromium Picolinate on Insulin Sensitivity in Type 2 Diabetes

Comparison of Combination Therapy vs Single Agent Therapy for Treatment of Urge Incontinence.

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus

Dose Range Finding Study of Bimagrumab in Sarcopenia

A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.

Melatonin and the Metabolic Syndrome

Impact of Metformin in Teens With Polycystic Ovary Syndrome (PCOS) on Oral Contraceptive Therapy

The Diabetes Prevention Trial of Type 1 Diabetes (DPT-1)

Effect of Alpelisib in Healthy Volunteers

A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus

Blood Sugar Take Care and Glucose Metabolism

Sunfiber and the Microbiota

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a New Formulation of Oritavancin in Healthy Volunteers

Ketone Ester And Salt (KEAS) in Older Adults

Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917

Single-Dose Intravenous Inositol Pharmacokinetics in Preterm Infants

Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients